

REMARKS

Claims 2 and 7 are hereby cancelled, without prejudice. The remaining claims, with the exception of claim 37, are amended to further clarify and define the scope of Applicants' claimed invention. Claims 1, 5, 40, and 42 are amended so as to better define the oxygen content of the composition elements of those claims. These claim amendments are supported by the originally filed specification and claims. The remaining claim amendments are largely nonsubstantive and do not limit the scope of the amended claims. Accordingly, the claim amendments add no new matter.

Claims 1, 3-6, and 8-42 are pending. Claims 1, 5, 37, 40, and 42 are the only pending independent claims.

The Office Action of July 24, 2003 rejected claims 1-36 and (apparently) claims 39-42 under 35 U.S.C. § 112, first paragraph, for allegedly failing to comply with the written description requirement. Specifically, the Office action objected to the use of the phrase "low oxygen content" in these claims. The Office Action indicated that claims 37 and 38 were allowable and that the other claims would be allowable if rewritten or amended to overcome the Section 112 rejection.


Applicants respectfully request reconsideration of this rejection in view of the foregoing amendments inasmuch as the phrase "low oxygen content" has been removed from the pending claims by the present amendment.

Attorney's Docket No. 6248.200-US
S/N 10/068,224 Filed May 2, 2002
Express Mail Label No. EV 246879215 US

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Date: November 24, 2003

Respectfully submitted,



Len S. Smith, Reg. No. 43,139
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE